Novartis

At Novartis, we're committed to reimagining the future of cancer care. At the heart of our mission lies a commitment to revolutionizing cancer care by addressing the pressing unmet needs of patients living with diverse types of cancer. With a broad oncology portfolio, we are dedicated to addressing these needs and developing innovative therapies that bring hope to patients and their loved ones. By exploring innovative therapies, we're pioneering new standards of care for patients worldwide. Learn more here: https://lnkd.in/gHheFZFp

This Pride Month, we want to spotlight the impact of our Pride Employee Resource Groups, who play a critical role in connecting and supporting our global LGBTQI+ and ally community at Novartis. By providing a safe space to share lived experiences, they help spark ideas that create positive change for our people and patients. Through these grassroots efforts and ongoing collaborations with organizations such as Stonewall and myGwork - LGBTQ+ Business Community, we are committed to driving LGBTQI+ equity and inclusion together. To find out more about LGBTQI+ Equity at Novartis, visit: https://lnkd.in/g9WxcSPK #PRIDE2024 #ThriveTogether

Collaboration with the patient community and medical experts is paramount in enabling our continued innovation for cancer patients with #Radioligandtherapy (RLT). #ASCO24

More than 20 years ago, a first-of-its-kind targeted therapy marked a turning point for the treatment of the blood cancer chronic myeloid leukemia (CML) and ushered in a new era of precision medicine. When follow-up medicines arrived a few years later, even more patients had the opportunity to benefit. But a gap in care remained—driving a continued pursuit to offer new treatment options. Read more about our relentless commitment to CML innovation: https://lnkd.in/gZr4RcBj

This #ASCO2024, Novartis is proud to present data from our Phase III ASC4FIRST trial for patients with newly diagnosed chronic myeloid leukemia (CML).

Today is World MS Day. Join the MSIF and MS community in the #MyMSDiagnosis campaign to raise awareness about the challenges faced in diagnosing MS. From first symptoms onward, people living with MS should feel empowered to actively share their voice. Because their voices and experiences matter. It matters from diagnosis onwards and through research and continued clinical and healthcare advancements, so people living with MS can have access to the best care available. At Novartis, we are excited to show our support for the global MS community by advocating for early and accurate diagnosis for all those affected by MS. Let's unite in solidarity and make a difference! Learn more about how you can support the campaign today: go.novartis.social/450eje5 #WorldMSDay #MS #MultipleSclerosis #ReimaginingNeuroscience

As pioneers in #RadioligandTherapy (RLT), we have bolstered our manufacturing capacity to meet present and future demand. Our teams at sites around the globe—including our newly opened, cutting-edge Indianapolis facility—are focused on optimizing the complex RLT manufacturing process to streamline the delivery of these medicines for people living with advanced cancers. Learn more about our commitment powered by manufacturing excellence. https://lnkd.in/gxvkRiij

Hope and science are a powerful combination.   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   But in the years that followed, unprecedented investments in combatting the disease saved 12 million lives and prevented 2 billion cases.   At Novartis, we celebrate all the people who helped make this possible.   But progress has stalled, and we need to act now to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria | Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Harvard T.H. Chan School of Public Health | Bernhards Ogutu

In part of the immune system called the complement system, the alternative pathway constantly monitors the body for threats and amplifies the complement response when triggered. In C3 glomerulopathy (C3G), dysregulation of the alternative complement pathway triggers the formation of C3 protein deposits in the kidneys, which causes inflammation and leads to progressive kidney damage and loss of kidney function. Understanding the underlying disease drivers in C3G is crucial to developing targeted therapies that can slow disease progression and alleviate symptoms for people living with this rare kidney disease. To find out more, visit our website: https://lnkd.in/gj-cDNA4

For people living with C3 glomerulopathy (C3G), a rare and progressive kidney disease, the symptoms can have a considerable impact on day-to-day life. At Novartis, we're raising awareness of this rare kidney disease and the current unmet needs that are yet to be addressed. Read more: https://lnkd.in/g-2i7Qcd